Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 41

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 41
---
, therefore, may be highly uncertain.
Uncertainties and risks that we face include the following:

| ● | our pending or future patent applications may not result in the issuance of patents;                                                                                                                                                          |
| ● | the scope of any existing or future patent protection may not exclude competitors or provide competitive advantages to us;                                                                                                                    |
| ● | our patents may not be held valid or enforceable if subsequently challenged;                                                                                                                                                                  |
| ● | other parties may claim that our products and designs infringe the proprietary rights of others—even if we are successful in defending our patents and proprietary rights, the cost of such litigation may adversely affect our business; and |
| ● | other parties may develop similar products, duplicate our products, or design around our patents.                                                                                                                                             |

The patent prosecution process
is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent
applications at a reasonable cost or in a timely manner, or in all jurisdictions. We may choose not to seek patent protection for certain
innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents
or other intellectual property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable
aspects of our developments before it is too late to obtain patent protection.

In addition, the laws of foreign
jurisdictions may not protect our rights to the same extent as the laws of the United States. For example, most countries outside of the
United States do not allow patents for methods of treating the human body. This may preclude us from obtaining method patents outside
of the United States having similar scope to those we have obtained or may obtain in the future in the United States. Changes in either
the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or
narrow the scope of our patent protection.

Moreover, we may be subject
to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or patent offices in foreign
jurisdictions, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference
proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate, our patent rights,